Y. Dodurga, L. Elmas, Mücahit Seçme, Nazlı Demirkıran, Ç. BİRAY AVCI, G. Bagci, Sevda Sağ, Lale Şatıroğlu Tufan
{"title":"索拉非尼和多柔比星对白血病细胞中 URG4/URGCP 的凋亡和细胞周期效应的研究","authors":"Y. Dodurga, L. Elmas, Mücahit Seçme, Nazlı Demirkıran, Ç. BİRAY AVCI, G. Bagci, Sevda Sağ, Lale Şatıroğlu Tufan","doi":"10.31362/patd.1476105","DOIUrl":null,"url":null,"abstract":"Leukemia, characterized by abnormal proliferation of blood cells, primarily affects leukocytes but can also impact other blood cells. Treatment typically involves stem cell transplants, radiotherapy, and chemotherapy, although chemotherapy can cause significant damage to healthy cells while targeting cancer cells. The effects of anti-cancer drugs like Sorafenib (SOR) and Doxorubicin (DOX) in leukemia treatment have been studied. Sorafenib, impacting various cellular signaling pathways, has proven effective in cancer therapy. On the other hand, Doxorubicin interacts with DNA to halt cell replication, leading to cell death. The impact of these drugs on apoptosis and the cell cycle in leukemia cells has been investigated. The study aims to examine the effects of DOX and SOR on URG4/URGCP mRNA levels in K562 and HL-60 leukemia cells, elucidating their impact on apoptosis and the cell cycle. This research seeks to understand the cellular effects of drugs used in leukemia treatment, contributing valuable insights to drug development processes in leukemia therapy.","PeriodicalId":506150,"journal":{"name":"Pamukkale Medical Journal","volume":"33 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigation of the Apoptotic and Cell Cycle Effects of Sorafenib and Doxorubicin on URG4/URGCP in Leukemia Cells\",\"authors\":\"Y. Dodurga, L. Elmas, Mücahit Seçme, Nazlı Demirkıran, Ç. BİRAY AVCI, G. Bagci, Sevda Sağ, Lale Şatıroğlu Tufan\",\"doi\":\"10.31362/patd.1476105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Leukemia, characterized by abnormal proliferation of blood cells, primarily affects leukocytes but can also impact other blood cells. Treatment typically involves stem cell transplants, radiotherapy, and chemotherapy, although chemotherapy can cause significant damage to healthy cells while targeting cancer cells. The effects of anti-cancer drugs like Sorafenib (SOR) and Doxorubicin (DOX) in leukemia treatment have been studied. Sorafenib, impacting various cellular signaling pathways, has proven effective in cancer therapy. On the other hand, Doxorubicin interacts with DNA to halt cell replication, leading to cell death. The impact of these drugs on apoptosis and the cell cycle in leukemia cells has been investigated. The study aims to examine the effects of DOX and SOR on URG4/URGCP mRNA levels in K562 and HL-60 leukemia cells, elucidating their impact on apoptosis and the cell cycle. This research seeks to understand the cellular effects of drugs used in leukemia treatment, contributing valuable insights to drug development processes in leukemia therapy.\",\"PeriodicalId\":506150,\"journal\":{\"name\":\"Pamukkale Medical Journal\",\"volume\":\"33 9\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pamukkale Medical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31362/patd.1476105\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pamukkale Medical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31362/patd.1476105","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
白血病的特征是血细胞异常增殖，主要影响白细胞，但也可能影响其他血细胞。治疗通常包括干细胞移植、放疗和化疗，但化疗在针对癌细胞的同时，也会对健康细胞造成重大损害。索拉非尼（Sorafenib，SOR）和多柔比星（Doxorubicin，DOX）等抗癌药物在白血病治疗中的作用已得到研究。索拉非尼能影响各种细胞信号通路，已被证明对癌症治疗有效。另一方面，多柔比星与 DNA 相互作用，阻止细胞复制，导致细胞死亡。这些药物对白血病细胞凋亡和细胞周期的影响已得到研究。本研究旨在考察 DOX 和 SOR 对 K562 和 HL-60 白血病细胞中 URG4/URGCP mRNA 水平的影响，阐明它们对细胞凋亡和细胞周期的影响。这项研究旨在了解白血病治疗药物对细胞的影响，为白血病治疗药物的开发过程提供有价值的见解。
Investigation of the Apoptotic and Cell Cycle Effects of Sorafenib and Doxorubicin on URG4/URGCP in Leukemia Cells
Leukemia, characterized by abnormal proliferation of blood cells, primarily affects leukocytes but can also impact other blood cells. Treatment typically involves stem cell transplants, radiotherapy, and chemotherapy, although chemotherapy can cause significant damage to healthy cells while targeting cancer cells. The effects of anti-cancer drugs like Sorafenib (SOR) and Doxorubicin (DOX) in leukemia treatment have been studied. Sorafenib, impacting various cellular signaling pathways, has proven effective in cancer therapy. On the other hand, Doxorubicin interacts with DNA to halt cell replication, leading to cell death. The impact of these drugs on apoptosis and the cell cycle in leukemia cells has been investigated. The study aims to examine the effects of DOX and SOR on URG4/URGCP mRNA levels in K562 and HL-60 leukemia cells, elucidating their impact on apoptosis and the cell cycle. This research seeks to understand the cellular effects of drugs used in leukemia treatment, contributing valuable insights to drug development processes in leukemia therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
